Spliced XBP1 Levels Determine Sensitivity of Multiple Myeloma Cells to Proteasome Inhibitor Bortezomib Independent of the Unfolded Protein Response Mediator GRP78

Overview of attention for article published in Frontiers in oncology, January 2020

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 26 Dimensions

Readers on

mendeley: 39 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 26 publications that cite this research output.

26

The most recent citing publications are shown below. View all 26 publications that cite this research output on Dimensions.

MiR-34c-5p Inhibition Affects Bax/Bcl2 Expression and Reverses Bortezomib Resistance in Multiple Myeloma Cells

Article in Indian Journal of Hematology and Blood Transfusion (April 2024)

Chromatin Profiles Are Prognostic of Clinical Response to Bortezomib-Containing Chemotherapy in Pediatric Acute Myeloid Leukemia: Results from the COG AAML1031 Trial

Article in Cancers (April 2024)

Distinct Pathway Activities are Associated with Prognosis and Response to Bortezomib- containing Treatment in MCL1-M Based Molecular Subtypes of Multiple Myeloma

Preprint in Research Square (March 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.